DAFNA Capital Management LLC lifted its holdings in shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR) by 187.2% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 204,808 shares of the company’s stock after buying an additional 133,488 shares during the quarter. Voyager Therapeutics comprises 1.3% of DAFNA Capital Management LLC’s investment portfolio, making the stock its 27th biggest position. DAFNA Capital Management LLC owned about 0.76% of Voyager Therapeutics worth $1,835,000 as of its most recent SEC filing.

Other hedge funds have also made changes to their positions in the company. Hershey Trust Co. lifted its stake in shares of Voyager Therapeutics by 163.0% during the 2nd quarter. Hershey Trust Co. now owns 14,394 shares of the company’s stock valued at $129,000 after buying an additional 8,921 shares in the last quarter. Fiduciary Trust Co. lifted its stake in shares of Voyager Therapeutics by 19.1% during the 1st quarter. Fiduciary Trust Co. now owns 108,561 shares of the company’s stock valued at $1,437,000 after buying an additional 17,386 shares in the last quarter. Wellington Management Group LLP lifted its stake in shares of Voyager Therapeutics by 17.4% during the 1st quarter. Wellington Management Group LLP now owns 131,312 shares of the company’s stock valued at $1,739,000 after buying an additional 19,450 shares in the last quarter. Teachers Advisors LLC lifted its stake in shares of Voyager Therapeutics by 9.8% during the 4th quarter. Teachers Advisors LLC now owns 20,604 shares of the company’s stock valued at $262,000 after buying an additional 1,847 shares in the last quarter. Finally, Wells Fargo & Company MN lifted its stake in shares of Voyager Therapeutics by 114.4% during the 1st quarter. Wells Fargo & Company MN now owns 83,577 shares of the company’s stock valued at $1,107,000 after buying an additional 44,599 shares in the last quarter. Institutional investors own 40.70% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This piece of content was posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this piece of content on another website, it was illegally stolen and republished in violation of United States and international trademark and copyright laws. The legal version of this piece of content can be accessed at https://www.thecerbatgem.com/2017/10/05/dafna-capital-management-llc-acquires-133488-shares-of-voyager-therapeutics-inc-vygr.html.

A number of analysts recently commented on VYGR shares. Zacks Investment Research cut shares of Voyager Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, July 13th. Chardan Capital reiterated a “hold” rating on shares of Voyager Therapeutics in a research note on Sunday, September 10th. ValuEngine upgraded shares of Voyager Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, September 30th. Stifel Nicolaus reiterated a “buy” rating and issued a $33.00 target price on shares of Voyager Therapeutics in a research note on Tuesday, June 27th. Finally, Cowen and Company reiterated a “buy” rating on shares of Voyager Therapeutics in a research note on Tuesday, August 8th. Two research analysts have rated the stock with a sell rating, two have assigned a hold rating and seven have given a buy rating to the company’s stock. Voyager Therapeutics has a consensus rating of “Hold” and a consensus target price of $24.83.

Voyager Therapeutics, Inc. (VYGR) traded down 0.89% during mid-day trading on Thursday, reaching $20.07. 248,323 shares of the company’s stock traded hands. Voyager Therapeutics, Inc. has a 12-month low of $8.10 and a 12-month high of $22.95. The stock has a 50 day moving average of $14.09 and a 200 day moving average of $10.99. The company’s market cap is $539.94 million.

Voyager Therapeutics (NASDAQ:VYGR) last posted its quarterly earnings results on Tuesday, August 8th. The company reported ($0.73) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.62) by ($0.11). The firm had revenue of $1.18 million during the quarter, compared to the consensus estimate of $3.27 million. Voyager Therapeutics had a negative return on equity of 46.15% and a negative net margin of 712.22%. On average, equities research analysts predict that Voyager Therapeutics, Inc. will post ($2.84) earnings per share for the current fiscal year.

In other Voyager Therapeutics news, insider Bernard Ravina sold 16,470 shares of the company’s stock in a transaction that occurred on Monday, September 11th. The shares were sold at an average price of $12.87, for a total value of $211,968.90. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Over the last quarter, insiders sold 27,450 shares of company stock valued at $321,769. Company insiders own 8.00% of the company’s stock.

Voyager Therapeutics Profile

Voyager Therapeutics, Inc is a clinical-stage gene therapy company. The Company focuses on developing treatments for patients suffering from severe diseases of the central nervous system (CNS). The Company’s pipeline consists of programs for CNS indications, including advanced Parkinson’s disease; a monogenic form of amyotrophic lateral sclerosis (ALS); Huntington’s disease; Friedreich’s ataxia; frontotemporal dementia/Alzheimer’s disease, and severe chronic pain.

Institutional Ownership by Quarter for Voyager Therapeutics (NASDAQ:VYGR)

Receive News & Stock Ratings for Voyager Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics Inc. and related stocks with our FREE daily email newsletter.